Proteomics Shared Resource
蛋白质组学共享资源
基本信息
- 批准号:10113579
- 负责人:
- 金额:$ 16.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-01 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:AchievementAntigensAreaArizonaBasic ScienceBreast AdenocarcinomaCXCR4 geneCell LineClinicComplexComprehensive Cancer CenterComputers and Advanced InstrumentationConsultationsDataData AnalysesData CollectionData SetDevelopmentDiseaseElectronic MailExperimental DesignsFee-for-Service PlansFloorFloridaFractionationFreezingFundingFutureGenomicsGlioblastomaGlycoproteinsGrantHumanIn VitroInvestigationKnowledgeLabelMalignant NeoplasmsMalignant neoplasm of ovaryMass Spectrum AnalysisMayo Clinic Cancer CenterMedicalMethodologyMethodsMolecularMyelogenousOncoproteinsPancreasPeer ReviewPeptide Sequence DeterminationPeptide SynthesisPeptidesPhenotypePhosphoproteinsPhosphorylation SitePolysaccharidesPost Translational Modification AnalysisPost-Translational Protein ProcessingPreparationProtein AnalysisProtein ChemistryProteinsProteomeProteomicsProteomics Shared ResourceResource SharingResourcesSPINK1 geneSamplingScienceServicesSignal TransductionSiteSoftware ToolsSquamous Cell Lung CarcinomaStandardizationT cell therapyT-LymphocyteTissuesTranscription CoactivatorTransforming Growth Factor betaVendorWorkanticancer researchcostdata acquisitiondata managementdeep sequencingdesignexperienceimprovedinformatics toolinsightinstrumentinstrumentationion mobilitymembermigrationnew technologyoperationphosphoproteomicspreventprogramsproteogenomicsrecruitscaffoldservice providerssquare footstemnesstandem mass spectrometrytitanium dioxidetoolweb portalweb site
项目摘要
PROTEOMICS SHARED RESOURCE PROJECT SUMMARY
The Mayo Clinic Cancer Center (MCCC) Proteomics Shared Resource (PRO) is a full-service facility that
provides essential services in peptide synthesis, protein analysis, protein and peptide separation, mass
spectrometry, proteomics applications, and expertise in project planning, sample preparation, data acquisition
and analysis. The PRO occupies a total of 4920 sq. ft. on the 3rd floor of the Medical Sciences Building, and is
located at the Mayo Clinic in Rochester (MCR) site. The 8 PRO staff members have broad knowledge and
expertise in the services provided. The PRO Director, Dr. Daniel J. McCormick, provides visionary direction,
planning, recruitment, and executive decisions regarding all operations, staffing, and services. Working with
institutional committees and centers for over 33 years, Dr. McCormick has been able to provide scientific
direction and support for high-end core instrumentation, and new technologies in protein chemistry, proteomics
and mass spectrometry (MS) to support Programs of MCCC members in cancer research. In the previous
funded period, 6 new service-lines (e.g., label-free differential proteomics, expanded phosphoproteomics by
SCX fractionation and TiO2 enrichment, proteomics analysis of FFPE and Frozen tissue, high/low pH LC
sample fractionation, de novo MS/MS protein sequencing, and MS analysis of complex glycans) were
developed to support the protein analysis needs of MCCC members. Scientific achievements include:
identification of key proteins that interact with TAT2 protein in myeloid cancers; development of agents that
inhibit TGFß action (via SMAD signaling) and prevent glioblastoma migration in PDX cell lines; identification of
key phosphoproteins (e.g., CXCR4) downregulated in Alisertib-treated human breast adenocarcinoma;
mapping sites of phosphorylation in SOX2, a transcriptional activator of “stemness” phenotype in lung
squamous cell carcinoma; synthesis of oncoprotein antigens for in vitro activation of naïve T-cells in adoptive
T-cell therapies to treat cancer (e.g., pancreatic); and differential analysis of proteins activated by SPINK1 in
ovarian cancer proliferation. PRO utilization by MCCC members has been strong with a total average usage of
51% by 99 members (72 peer-reviewed) in the current funded period (2013-2017). The PRO is used by MCCC
members from all 3 sites, including 12 members from Mayo Clinic in Florida and 5 members from Mayo Clinic
in Arizona. The PRO provides free consultation, project design, and data interpretation to MCCC members,
and provides its services on fee-for-service basis; standardized forms for project and service requests are on
the resources' internal web site. Comparison of rates for many services of the PRO to external cores and
vendors, was completed in 2017 and indicated that core rates were highly competitive. Future directions of the
PRO include: deep sequencing proteomics with advanced MS instrumentation and data-independent
acquisition (DIA) methods; top-down MS protein sequencing; ion mobility separation (IMS) mass spectrometry;
proteogenomics integration of genomics/proteomics data sets, and MS analysis of glycoproteins.
Proteomics共享资源项目摘要
马约诊所癌症中心(MCCC)蛋白质组学共享资源(PRO)是一个提供全方位服务的机构,
提供肽合成、蛋白质分析、蛋白质和肽分离、质谱分析
光谱学、蛋白质组学应用以及项目规划、样品制备、数据采集方面的专业知识
和分析PRO占地4920平方米。英尺在医学科学大楼的三楼,
位于罗切斯特(MCR)研究中心的马约诊所。8名专业干事知识渊博,
提供服务的专业知识。专业主任,丹尼尔J麦考密克博士,提供有远见的方向,
有关所有运营、人员配备和服务的规划、招聘和执行决策。使用
机构委员会和中心超过33年,麦考密克博士已经能够提供科学的
指导和支持高端核心仪器,以及蛋白质化学,蛋白质组学的新技术
和质谱(MS),以支持MCCC成员在癌症研究中的计划。上一
在供资期间,6个新的服务项目(例如,无标记差异蛋白质组学,扩展磷酸化蛋白质组学,
SCX分级分离和TiO 2富集,FFPE和冷冻组织的蛋白质组学分析,高/低pH LC
样品分级分离、从头MS/MS蛋白质测序和复杂聚糖的MS分析)。
开发用于支持MCCC成员的蛋白质分析需求。科学成就包括:
在骨髓癌中鉴定与TAT 2蛋白相互作用的关键蛋白;开发
在PDX细胞系中抑制TGF β 1作用(通过SMAD信号传导)并防止胶质母细胞瘤迁移;
关键磷蛋白(例如,CXCR 4)在Alisertib治疗的人乳腺癌中下调;
肺“干性”表型转录激活因子SOX 2磷酸化位点定位
鳞状细胞癌;用于过继免疫中体外激活幼稚T细胞的癌蛋白抗原的合成
治疗癌症的T细胞疗法(例如,胰腺);和差异分析的蛋白质激活SPINK 1在
卵巢癌细胞增殖MCCC成员的PRO使用率一直很高,总平均使用率为
51%由99名成员(72名同行评审)在当前资助期间(2013-2017年)。PRO由MCCC使用
来自所有3个研究中心的成员,包括佛罗里达州马约诊所的12名成员和马约诊所的5名成员
在亚利桑那州专业档案室为MCCC成员提供免费咨询、项目设计和数据解释,
,并以收费服务方式提供服务;项目和服务要求的标准表格载于
资源的内部网站。专业干事的许多服务与外部核心服务的费率比较,
供应商,于2017年完成,并表示核心费率极具竞争力。的未来方向
PRO包括:使用先进的MS仪器和数据独立的深度测序蛋白质组学
采集(DIA)方法;自顶向下MS蛋白质测序;离子迁移率分离(IMS)质谱;
基因组学/蛋白质组学数据集的蛋白质组学整合,以及糖蛋白的MS分析。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AKHILESH PANDEY其他文献
AKHILESH PANDEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AKHILESH PANDEY', 18)}}的其他基金
Personalized Therapy of Hormone Refractory Breast Cancer
激素难治性乳腺癌的个体化治疗
- 批准号:
8895506 - 财政年份:2015
- 资助金额:
$ 16.09万 - 项目类别:
Personalized Therapy of Hormone Refractory Breast Cancer
激素难治性乳腺癌的个体化治疗
- 批准号:
9247704 - 财政年份:2015
- 资助金额:
$ 16.09万 - 项目类别:
Establishing clinical utility of CSF biomarkers for PD
建立脑脊液生物标志物对 PD 的临床应用
- 批准号:
8882847 - 财政年份:2014
- 资助金额:
$ 16.09万 - 项目类别:
DEVELOPMENT OF SITE FOR DEPOSITION OF PROTEOMIC, OTHER PROTEIN ANALYTICAL DATA
开发用于沉积蛋白质组和其他蛋白质分析数据的位点
- 批准号:
7723077 - 财政年份:2008
- 资助金额:
$ 16.09万 - 项目类别:
TCP3: QUALITATIVE & QUANTITATIVE PROTEOMIC ANALYSIS OF LYSINE MODIFICATIONS
TCP3:定性
- 批准号:
7724687 - 财政年份:2008
- 资助金额:
$ 16.09万 - 项目类别:
DEVELOPMENT OF SITE FOR DEPOSITION OF PROTEOMIC, OTHER PROTEIN ANALYTICAL DATA
开发用于沉积蛋白质组和其他蛋白质分析数据的位点
- 批准号:
7602071 - 财政年份:2007
- 资助金额:
$ 16.09万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 16.09万 - 项目类别:
Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 16.09万 - 项目类别:
Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 16.09万 - 项目类别:
Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 16.09万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 16.09万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 16.09万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 16.09万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 16.09万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 16.09万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 16.09万 - 项目类别:














{{item.name}}会员




